Osmind

We are excited to announce a landmark collaboration with the American Psychiatric Association (APA) to advance quality psychiatric care and accelerate research. "At Osmind, we emphasize the importance of clinicians participating in evidence-generating medicine to help shape the future of mental health care, especially as the psychiatric field begins to embrace new treatments and precision psychiatry,” says Carlene MacMillan, MD, Chief Medical Officer of Osmind. “Clinicians in private practice juggle many competing demands so it is crucial we make participation both easy and worthwhile to them." To make participation in evidence-generating medicine easier for busy private practitioners, we’re integrating APA's diagnostic and outcomes measures directly into the Osmind EHR. We're starting with the DSM-5-TR Self-Rated Level 1 Cross-Cutting Symptom Measure, which joins our library of 40+ measures, enabling clinicians to contribute to research at the point of care. We’ll also explore an integration between the Osmind EHR and PsychPRO so that clinicians using the Osmind EHR can participate effortlessly in the PsychPRO registry. "PsychPRO is the tool healthcare organizations need to guide their efforts to deliver quality mental health care and improve patient outcomes," says Nitin Gogtay, M.D., APA Chief of Research and Deputy Medical Director. "Our collaboration with Osmind will allow us to strengthen PsychPRO today, and long-term offers promise to broaden the scope of our impact on psychiatry and on the patients we serve.” We are delighted to work with the APA, and proud to enable independent practices to contribute to the evolution of the field and elevate their own evidence-based practices. https://lnkd.in/g4RU7Ftt

As the #1 ketamine-tailored EHR, Osmind is excited to exhibit in Detroit at the ASKP3 conference, “Ketamine In Psychiatric Practice: Mastering the Essentials." When: September 12-14 Starting or growing your private practice and want to explore the science behind ketamine treatments for depression? This is a great conference to attend and network with other forward-thinking psychiatrists. If you're attending, be sure to come and meet the Osmind team! Learn more about the course in the comments below.

We're very excited to announce this month's members-only webinar! The FDA Said No, What’s Next? Exploring the Field’s Next Chapter After the MDMA Decision Register: https://buff.ly/3WM1dxm In case you missed the news last week, the FDA officially denied Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy, requesting a new Phase III trial be conducted. This was a huge blow to the practitioners and patients who were hoping that MDMA would soon be a legal option to address PTSD, a condition where no other therapy has shown the same levels of efficacy as MDMA-assisted therapy. So you may have questions, like, “When is the next psychedelic medicine likely to be up for FDA approval” and “Which medicine may be the next to reach that stage?” And you may also want an update on what psychedelics (like ketamine) are legally available and how might they serve as a stand-in for the others while we await FDA approvals. This month we are truly fortunate to have panelists working in various arenas within psychedelic medicine and research to help lead a discussion regarding what psychedelic options are currently available and what’s to come, including: • Which psychedelic medicines are next in the FDA pipeline • When might we see another psychedelic therapy up for FDA approval • How can we utilize the available psychedelic options in the meantime …and much more! Panelists joining for this event are: Owen Muir MD DFAACAP | Co-Founder, Fermata; Chief Medical Officer, iRxReminder LLC Carlene MacMillan, MD, FCTMSS,DFAACAP | Co-Founder, Fermata; Chief Medical Officer, Osmind As always, there will be ample time for audience Q&A, so you’ll get to interact with the panelists directly! So please join us for this live panel discussion on Thursday, August 29th at 5 pm Pacific, 8 pm Eastern. Register: https://buff.ly/3WM1dxm

🩺 The DSM-5-TR Level 1 Cross-Cutting Symptom Measure (DSM-XC) is the stethoscope of psychiatry – but diagnosis doesn't stop at the first listen! Just as a primary care physician might follow up with blood tests or a specialist referral, mental health clinicians need targeted assessments for a comprehensive evaluation. Here's your guide to the next steps: 📊 When DSM-XC flags these domains, consider these follow-ups: - Depression: PHQ-9 - Anger: PROMIS Emotional Distress-Anger-Short Form - Mania: Altman Self-Rating Mania Scale (ASRM) - Anxiety: GAD-7 - Sleep: PROMIS-Sleep Disturbance-Short Form Want to dive deeper? Our latest blog post breaks down recommended measures for all 13 DSM-XC domains, helping you build a more precise and personalized assessment toolkit. https://lnkd.in/gKc9AMQh

We’re proud to share that our founder, David Feifel, MD, PhD, was recently featured on the "Psychiatry Tomorrow" podcast by Osmind! In this insightful episode titled "Entering the Golden Era of Psychiatry," Dr. Feifel delves into the cutting-edge advancements in the field he contributed to and shares his vision for the future of mental health treatment. His pioneering work at Kadima Neuropsychiatry continues to push the boundaries of what’s possible, and we’re honored to have him lead our team. Tune in to hear Dr. Feifel's thoughts on the transformative changes taking place in psychiatry and how these innovations are shaping the future of patient care.

📢 FDA Decision on MDMA-Assisted Therapy: What It Means for Mental Health Care The FDA's recent decision to deny approval for MDMA-assisted therapy marks a significant moment in the field of psychedelic medicine. While this setback delays access for the 13+ million Americans suffering from PTSD, it also highlights the critical need for rigorous training and safety protocols in this emerging field. Our Chief Medical Officer, Carlene MacMillan, MD, FCTMSS,DFAACAP, recently joined Zachary Haigney on The Trip Report by Beckley Waves podcast to unpack the implications of this decision. Key points discussed include: -The impact on therapist training and treatment accessibility -Lessons learned from the approval process -The future landscape of psychedelic-assisted therapies -Next steps for researchers and clinicians in the field This conversation builds on our recent Psychiatry Tomorrow episode, where we explored the complexities surrounding MDMA-assisted therapy with leading experts. For mental health professionals navigating this evolving landscape, these discussions offer crucial insights into the future of PTSD treatment and psychedelic medicine. We remain committed to advancing evidence-based practices and supporting the development of comprehensive training guidelines in psychedelic-assisted therapies. What are your thoughts on the FDA's decision and its implications for mental health care? Share below! 💬 https://lnkd.in/guUHybwY

We're excited to welcome Dr. Robert M. Berman, M.D., pioneer of ketamine for depression, as Osmind's new Strategic Advisor! Dr. Rob Berman's groundbreaking work includes the first study of IV ketamine in depression patients, offering new hope for treatment-resistant cases. His expertise spans academia and biopharma, with leadership roles at Biohaven Pharmaceuticals, Bristol-Myers Squibb, and Pfizer. "We're at a critical juncture in neuropsychiatry. Leveraging real-world evidence can accelerate breakthrough treatment development. I'm excited to work with Osmind to develop more effective, personalized treatments for mental health conditions." - Dr. Berman Dr. Berman's invaluable insights will guide Osmind's research initiatives, ensuring we remain at the forefront of neuropsychiatric treatment innovation. Read the full announcement: https://lnkd.in/dXThDFRH

IV ketamine is a beacon of hope for treatment-resistant depression. But how should clinicians make sense of the evidence to inform their practice? In this guide, Osmind Community Advisory Board member, Joe Pullara, M.D. shares insights on IV ketamine’s safety and advantages over at-home options. "No matter how you feel about the term 'treatment-resistant,' even the most conservative estimates report at minimum 1/3rd of patients do not respond to traditional serotonergic medications." Key IV ketamine insights: -50% response rate in real-world studies -30% remission rate in depression patients -80% of responders retained response at 1 month -Safer and more precise than at-home oral options -Can normalize Default Mode Network activity -Supervised administration ensures patient safety "IV ketamine represents a step in the right direction for treating depression, But with this optimism, we must remember it is a treatment, not a cure." Dive into Dr. Pullara's clinical observations and the evidence behind IV ketamine: https://lnkd.in/d72ijjYa

The DSM-5-TR Level 1 Cross-Cutting Measure: Your psychiatric stethoscope for holistic patient assessment. This free, research-backed tool covers 13 symptom domains, reducing diagnostic bias and aligning with modern transdiagnostic approaches. It's not just a screener—it's a gateway to more accurate diagnoses, improved patient engagement, and targeted treatment plans. Swipe through to discover 10 reasons why the DSM-XC should be part of your clinical toolkit. From supporting patient-centered care to future-proofing your practice, it's time to elevate your approach to mental health assessment. #PsychiatricAssessment #MentalHealthCare #DSM5TR #MeasurementBasedCare

Great analysis on MDMA-AT and the FDA from our Vice President of Scientific Affairs, L. Alison McInnes MD, MS!